Inicio
Markets
Charts & Ideas
Algo
Noticias
Store
Corredores
Descargar
Calendario económico
Señales Comerciales
WebTerminal
Pulse
/
para buscar: @user, $symbol, ...
Buscar
Entrada
Crear una cuenta
Español
English
Русский
中文
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
APLS
#1497
Apellis Pharmaceuticals, Inc. Common Stock
20.9
6
-4.42%
Sector:
Básica:
Profit Currency:
Rango diario
Rango anual
Cambio diario
-4.42%
Monthly Change
-6.05%
6 month change
-26.71%
Cambio anual
-19.38%
Cierres anteriores
21.9
3
Open
20.9
6
Bid
Ask
Low
20.9
6
High
20.9
6
Volumen
127
Markets
Acciones
Atención Sanitaria
APLS
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
Q4, 25
TTM
Key stats
Total common shares outstanding
124.39 M
125.52 M
125.68 M
126.29 M
126.53 M
127.83 M
—
Valuation ratios
Enterprise value
3.19 B
3.59 B
2.39 B
1.82 B
2.38 B
2.74 B
9.34 B
Price to earnings ratio
-14.42
-19.94
-12.15
-9.46
75.43
125.6
179.42
Price to sales ratio
4.95
5.06
3.5
2.86
2.83
3.25
12.45
Price to cash flow ratio
16.97
45
350.81
-430.27
71.79
71.97
64.29
Price to book ratio
3.67
17.3
3.04
2.75
3.03
8.81
17.62
Enterprise value to EBITDA ratio
—
-19.73
-10.92
-8.18
41.4
75.23
97.54
Profitability ratios
Return on assets %
0.06
0.04
0.11
0.05
0.2
-0.3
0.06
Return on equity %
0.24
0.16
0.56
0.27
0.54
-0.89
0.48
Return on invested capital %
53.03
33.66
116.07
49.12
270.29
-289.44
146.04
Gross margin %
95.68
97.69
85.97
101.68
100.17
99.55
387.38
Operating margin %
24.02
12.31
49.96
18.65
48.67
-142.25
-24.97
EBITDA margin %
-28.11
-14.41
-63.72
-16.72
48.92
-25.87
-57.39
Net margin %
29.19
17.11
55.29
23.61
47.04
-163.92
-37.98
Liquidity ratios
Quick ratio
3.73
3.81
3.62
3.16
3.1
2.7
12.58
Current ratio
4.36
4.25
4.08
3.77
3.54
3.14
14.53
Inventory turnover
0.06
0.05
0.29
-0.03
-0.01
0.01
0.26
Asset turnover
0.22
0.24
0.2
0.22
0.49
0.19
1.09
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
0.5
0.11
0.56
0.55
0.34
0.34
1.79
Long term debt to total equity ratio
1.91
0.41
2.76
2.9
0.9
0.98
7.54
Per share metrics
Operating cash flow per share
-0.27
-0.16
0.43
-0.04
0.08
-0.11
0.36
EBIT per share
-0.45
-0.25
-0.85
-0.24
1.72
-0.4
0.23
EBITDA per share
-0.45
-0.25
-0.85
-0.24
1.72
-0.4
0.24
Total debt per share
—
—
—
—
—
—
—
Cash per share
3.19
3.32
2.86
2.94
3.68
3.59
13.07
Net current asset value per share
6.71
6.37
5.8
6
7.62
7.82
27.23
Tangible book value per share
1.91
1.84
1.31
1.24
3.08
2.85
8.48
Working capital per share
5.17
4.87
4.38
4.4
5.47
5.32
19.57
Book value per share
1.91
1.84
1.31
1.24
3.08
2.85
8.48
Noticias
Apellis Q4 Loss Wider Than Expected, Revenues Decline Y/Y
H.C. Wainwright eleva el precio objetivo de Apellis por perspectivas de Syfovre
H.C. Wainwright eleva precio objetivo de Apellis por perspectivas de Syfovre
H.C. Wainwright raises Apellis stock price target on Syfovre outlook
Apellis Pharmaceuticals, Inc. (APLS) Q4 2025 Earnings Call Transcript
Apellis Pharma superaron 0.85$ las previsiones de BPA en el cuarto trimestre del año
Apellis Pharma supera por 0,85$ las previsiones de BPA en el cuarto trimestre del año
Apellis Pharma earnings beat by $0.85, revenue topped estimates
Apellis Pharmaceuticals, Inc. (APLS) Surpasses Q4 Earnings and Revenue Estimates
Apellis T4 2025: crecimiento dual de productos, camino a rentabilidad
Apellis 4T 2025: crecimiento dual de productos y camino a rentabilidad
Apellis Q4 2025 slides: dual product growth, path to profitability